Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Grundy, J. Plumb, M. Kaur, S. Lea, D. Singh (Manchester, United Kingdom). Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells. Eur Respir J 2014; 44: Suppl. 58, 1515

Member's Comments

No comment yet.

Related content which might interest you: The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Simvastatin suppresses the activity of Th2 and Tc2 cells in atopic asthma and in COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014